The project aims to increase uptake of all oral regimens for MDR/RR-TB through introduction of Xpert MDR/XDR for rapid drug susceptibility testing to rule-out fluoroquinolone resistance. All eligible will be enrolled on shorter, all-oral Bedaquiline containing regimens with capacity building for health workers and resilient community systems strengthening for case finding and treatment adherence.
